<DOC>
	<DOCNO>NCT00560716</DOCNO>
	<brief_summary>This phase I study investigational cancer drug , CYC116 , patient advance solid tumor .</brief_summary>
	<brief_title>A Phase I Pharmacologic Study CYC116 , Oral Aurora Kinase Inhibitor , Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Incurable advance solid tumor respond conventional therapy effective therapy exist Age &gt; =18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy â‰¥ 3 month Evaluable disease Adequate bone marrow function Adequate renal function Adequate liver function At least 3 week prior systemic treatment include investigational anticancer therapy , radiation therapy ; recover prior toxicity Able swallow capsule At least 3 week major surgery Agree practice effective contraception Previously untreated CNS metastasis progressive CNS metastasis document MRI scan perform 4 week longer last treatment CNS metastasis Currently receive radiotherapy , biological therapy , investigational agent Uncontrolled intercurrent illness Pregnant lactate woman Known HIVpositive Known active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>